Allergy Therapeutics plc provided revenues guidance for the six months ended December 31, 2019. Reported revenues for the six months ended December 31, 2019 are expected to have grown to £50.5 million (2018: £46.7 million) representing 9% growth on a constant currency basis (8% on reported basis). The Group is trading in line with Board expectations.